P738 Sustained clinical remission with vedolizumab in Moderate-to-Severe Crohn’s disease: A GEMINI 2 post hoc analysis of Week 14 remitters

Sustained clinical remission is a key treatment goal for Crohn’s disease (CD). Vedolizumab (VDZ), a gut-selective α4β7 integrin antagonist, was more effective than placebo (PLA) in achieving clinical remission after induction and maintenance therapy in patients with moderate-to-severe CD in the GEMINI 2 study. The label for VDZ recommends evaluation of clinical benefit at Week 14 after three doses (Weeks 0, 2 and 6). This post hoc analysis...